NovaBay Pharmaceuticals, Inc. (NBY)
- Previous Close
0.6150 - Open
0.6050 - Bid 0.6013 x 2200
- Ask 0.6600 x 900
- Day's Range
0.6050 - 0.6432 - 52 Week Range
0.3600 - 14.0000 - Volume
92,558 - Avg. Volume
2,649,284 - Market Cap (intraday)
2.966M - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-76.0400 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.30
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
novabay.comRecent News: NBY
View MorePerformance Overview: NBY
Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NBY
View MoreValuation Measures
Market Cap
3.00M
Enterprise Value
4.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.02
Price/Book (mrq)
--
Enterprise Value/Revenue
0.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-76.81%
Return on Assets (ttm)
-32.80%
Return on Equity (ttm)
-282.96%
Revenue (ttm)
13.88M
Net Income Avi to Common (ttm)
-16.68M
Diluted EPS (ttm)
-76.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
751k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
2.46M